COMBINED MIRTAZAPINE AND SSRI TREATMENT OF PTSD: A PLACEBO-CONTROLLED TRIAL

Overview

Journal Depress Anxiety

Publisher Wiley

Date 2015 Jun 27

PMID 26115513

Citations 13

Authors

Franklin R Schneier

Raphael Campeas

Jaime Carcamo

Andrew Glass

Roberto Lewis-Fernandez

Yuval Neria

Arturo Sanchez-Lacay

Donna Vermes

Melanie M Wall

Affiliations

Soon will be listed here.

Abstract

Background: Combined treatment with a selective serotonin reuptake inhibitor (SSRI) plus mirtazapine has shown superior efficacy in some studies of depression, but has not been studied in posttraumatic stress disorder (PTSD). This study aimed to assess acceptability of combined sertraline plus mirtazapine treatment for PTSD and to estimate its effect size relative to sertraline plus placebo.

Methods: Thirty-six adults with PTSD were randomized to 24 weeks of double-blind treatment with sertraline plus mirtazapine or sertraline plus placebo. Outcomes were analyzed with mixed effects models.

Results: The combined treatment group showed a significantly greater remission rate (P = .042) and improvement in depressive symptoms (P = .023) than the sertraline plus placebo group. There were no significant group differences in the two primary outcomes of treatment retention and PTSD severity, or in other secondary outcomes (sleep impairment, sexual functioning, quality of life, and physical and mental functioning), but the combined treatment group showed numerical advantages on all of these outcomes, and effect sizes relative to sertraline plus placebo ranged from small to moderate (d = .26-.63). Both treatments were well-tolerated, with significantly increased appetite but not weight gain in the combined treatment group.

Conclusion: Findings suggest that combined treatment of PTSD with sertraline plus mirtazapine may have clinically meaningful advantages in symptomatic improvement, relative to SSRI treatment alone, and acceptable tolerability. Combined treatment with an SSRI plus mirtazapine in PTSD deserves additional study as initial treatment or as an augmentation strategy for nonresponders to an SSRI.

Citing Articles

Effects of Antidepressants on Sleep in Post-traumatic Stress Disorder: An Overview of Reviews.

Lappas A, Polyzopoulou Z, Christodoulou N, Bozikas V, Samara M Curr Neuropharmacol. 2023; 22(4):749-805.

PMID: 37533247 PMC: 10845105. DOI: 10.2174/1570159X21666230801144328.

Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches.

Hoskins M, Bridges J, Sinnerton R, Nakamura A, Underwood J, Slater A Eur J Psychotraumatol. 2022; 12(1):1802920.

PMID: 34992738 PMC: 8725683. DOI: 10.1080/20008198.2020.1802920.

Bartova L, Dold M, Fugger G, Kautzky A, Mitschek M, Weidenauer A Depress Anxiety. 2021; 38(9):896-906.

PMID: 34110066 PMC: 8453858. DOI: 10.1002/da.23165.

Imagery rehearsal therapy and/or mianserin in treatment of refugees diagnosed with PTSD: Results from a randomized controlled trial.

Sandahl H, Jennum P, Baandrup L, Mortensen E, Carlsson J J Sleep Res. 2021; 30(4):e13276.

PMID: 33529449 PMC: 8365672. DOI: 10.1111/jsr.13276.

Pharmacotherapy of 1,044 inpatients with posttraumatic stress disorder: current status and trends in German-speaking countries.

Reinhard M, Seifert J, Greiner T, Toto S, Bleich S, Grohmann R Eur Arch Psychiatry Clin Neurosci. 2020; 271(6):1065-1076.

PMID: 33369692 PMC: 8354906. DOI: 10.1007/s00406-020-01223-x.

References

Pallanti S, Quercioli L, Bruscoli M . Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry. 2004; 65(10):1394-9. DOI: 10.4088/jcp.v65n1015. View

Zoellner L, Feeny N, Cochran B, Pruitt L . Treatment choice for PTSD. Behav Res Ther. 2003; 41(8):879-86. DOI: 10.1016/s0005-7967(02)00100-6. View

Roy-Byrne P, Berliner L, Russo J, Zatzick D, Pitman R . Treatment preferences and determinants in victims of sexual and physical assault. J Nerv Ment Dis. 2003; 191(3):161-5. DOI: 10.1097/01.NMD.0000055343.62310.73. View

Endicott J, Nee J, Harrison W, Blumenthal R . Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993; 29(2):321-6. View

Davidson J, Pearlstein T, Londborg P, Brady K, Rothbaum B, Bell J . Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry. 2001; 158(12):1974-81. DOI: 10.1176/appi.ajp.158.12.1974. View

Alfaro C, Lam Y, Simpson J, Ereshefsky L . CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol. 2000; 40(1):58-66. DOI: 10.1177/00912700022008702. View

Germain A, Hall M, Krakow B, Shear M, Buysse D . A brief sleep scale for Posttraumatic Stress Disorder: Pittsburgh Sleep Quality Index Addendum for PTSD. J Anxiety Disord. 2004; 19(2):233-44. DOI: 10.1016/j.janxdis.2004.02.001. View

Ehlers A, Hackmann A, Michael T . Intrusive re-experiencing in post-traumatic stress disorder: phenomenology, theory, and therapy. Memory. 2004; 12(4):403-15. DOI: 10.1080/09658210444000025. View

Breslau N . The epidemiology of posttraumatic stress disorder: what is the extent of the problem?. J Clin Psychiatry. 2001; 62 Suppl 17:16-22. View

10.

Tucker P, Potter-Kimball R, Wyatt D, Parker D, Burgin C, Jones D . Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. Psychopharmacol Bull. 2003; 37(3):135-49. View

11.

Blier P, Ward H, Tremblay P, Laberge L, Hebert C, Bergeron R . Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2009; 167(3):281-8. DOI: 10.1176/appi.ajp.2009.09020186. View

12.

Stander V, Thomsen C, Highfill-McRoy R . Etiology of depression comorbidity in combat-related PTSD: a review of the literature. Clin Psychol Rev. 2014; 34(2):87-98. DOI: 10.1016/j.cpr.2013.12.002. View

13.

Marshall R, Lewis-Fernandez R, Blanco C, Simpson H, Lin S, Vermes D . A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress Anxiety. 2006; 24(2):77-84. DOI: 10.1002/da.20176. View

14.

de Boer T . The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996; 57 Suppl 4:19-25. View

15.

McFarlane A . The longitudinal course of posttraumatic morbidity. The range of outcomes and their predictors. J Nerv Ment Dis. 1988; 176(1):30-9. DOI: 10.1097/00005053-198801000-00004. View

16.

Gentes E, Dennis P, Kimbrel N, Rissling M, Beckham J, Calhoun P . DSM-5 posttraumatic stress disorder: factor structure and rates of diagnosis. J Psychiatr Res. 2014; 59:60-7. DOI: 10.1016/j.jpsychires.2014.08.014. View

17.

McGahuey C, Gelenberg A, Laukes C, Moreno F, Delgado P, McKnight K . The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000; 26(1):25-40. DOI: 10.1080/009262300278623. View

18.

Roberts A, Gilman S, Breslau J, Breslau N, Koenen K . Race/ethnic differences in exposure to traumatic events, development of post-traumatic stress disorder, and treatment-seeking for post-traumatic stress disorder in the United States. Psychol Med. 2010; 41(1):71-83. PMC: 3097040. DOI: 10.1017/S0033291710000401. View

19.

Lewis J . Mirtazapine for PTSD nightmares. Am J Psychiatry. 2002; 159(11):1948-9. DOI: 10.1176/appi.ajp.159.11.1948-a. View

20.

Gradus J, Qin P, Lincoln A, Miller M, Lawler E, Sorensen H . Posttraumatic stress disorder and completed suicide. Am J Epidemiol. 2010; 171(6):721-7. DOI: 10.1093/aje/kwp456. View